An interventional study of Community Demonstrations and Redemption points in Chlorination, sponsored by University of Michigan. Recruiting at 1 site in Nigeria. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by University of Michigan · Not applicable, Interventional, and Prevention
Access to safe water remains a pressing public health challenge in Nigeria, where 67% of the population lacks safely managed drinking water and waterborne diseases cause an estimated 70,000 child deaths annually. Building on evidence that point-of-use chlorination is highly cost-effective in reducing diarrheal disease, this study evaluates a scalable, community-based chlorine distribution model through a cluster-randomized controlled trial (RCT) in Kano State. Thirty communities across four Local Government Areas will be randomly assigned to one of three groups: (i) 20 treatment communities receiving community demonstrations and local chlorine redemption points, (ii) 10 control communities where no intervention will be conducted. After 3 months, 5 control communities will receive an individual-level sensitization and a voucher program and 5 will remain pure control communities. The RCT aims to estimate the causal impact of the community-based intervention on household chlorination rates, water quality (E. coli contamination), and knowledge of safe water practices over six months. By rigorously testing a community-led water treatment model, this study contributes new evidence on sustainable and cost-effective approaches to expand safe water access in low-resource settings. The results will inform national and regional strategies for scaling point-of-use chlorination across sub-Saharan Africa.
877 studies on the registry are indexed under Diarrhea; 76 are open to participants now.
This study's planned enrollment of 700 is above the median of 137 across 738 interventional studies indexed under Diarrhea.
Browse Diarrhea studies →University of Michigan is the lead sponsor of 1,506 studies on the registry; 192 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 133 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Community Demonstrations and Redemption Points
Behavioral: Community Demonstrations · Behavioral: Redemption points
Neither community distributions will be conducted nor redemption points will be set-up during the study period
Facilitators will collaborate with local leaders, WASH officials and health facility staff in conducting community demonstrations introducing the chlorine product (WaterGuard+) to communities in the treatment group. Local leaders in the community will organize the meeting, while facilitators in the country will demonstrate how to use the product, what the correct dosage is, and explain the importance of water treatment. They will also show how village water is contaminated with Ecoli. These meetings will be targeted at eligible women (pregnant women and women with children under the age of 5), however all members of the community will be invited to attend. At the meeting, each attendee will be given one bottle of WaterGuard+, which is enough to treat drinking water for a household of 5 members for about a month, and 1,000 naira. Water Guard + is a 180g bottle of sodium dichloroisocyanurate (NaDCC) in granulated / powder form, produced and distributed by the Society for Family Health.
Study staff will set up at least one chlorine redemption point for each community. The location of the redemption point will be determined in consultation with the local community during Community Demonstrations. The redemption points could be health facilities, local shops/dispensaries/kiosks, local pharmacies, house of the village leader, CHW, or health staff or other suitable sites. Households will be able to visit the location and redeem a month's supply of a chlorine product. Distributors will use a redemption log to keep track of when participants redeem the chlorine product.
Treat drinking water with chlorine (tested in water sample)
Proportion of water samples with detectable chlorine in stored drinking water
Time frame: Measured up to 6 months of follow-up
Treat drinking water with chlorine (self-reported)
Proportion of women who reported using chlorine in the previous two days
Time frame: Measured up to 6 months of follow-up
Presence of E.coli
Proportion of water samples with detectable E.coli
Time frame: Measured up to 6 months of follow-up
Level of E.coli
Level of E-coli (in log10 MPN/100ml) in water samples
Time frame: Measured up to 6 months of follow-up
Unsafe risk of Coliform
Proportion of water samples with unsafe coliform ( \>100 colony forming units per 100mL)
Time frame: Measured up to 6 months of follow-up
Heard about chlorine
Proportion of women who ever heard about chlorine
Time frame: Measured up to 6 months of follow-up
Ever used chlorine
Proportion of women who ever used chlorine
Time frame: Measured up to 6 months of follow-up
Last used chlorine
Proportion of women who used chlorine yesterday or the day before
Time frame: Measured up to 6 months of follow-up
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.